J. Hassel

K. Kähler, S. Ugurel, L. Heinzerling, 2016, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

Diet-dependent toxicity of ipilimumab in metastatic melanoma.

A. Enk, P. Majenka, A. Dimitrakopoulou-Strauss, 2019, European journal of cancer.

Acute heart failure as a result of granulomatous myocarditis: case report on a patient with metastatic melanoma treated with dabrafenib and trametinib

A. Enk, K. Buder-Bakhaya, J. Winkler, 2018, Journal of the European Academy of Dermatology and Venereology : JEADV.

METRIC phase III study: Efficacy of trametinib (T), a potent and selective MEK inhibitor (MEKi), in progression-free survival (PFS) and overall survival (OS) compared with chemotherapy (C) in patients (pts) with BRAFV600/k mutant advanced or metastatic melanoma (MM).

J. Utikal, D. Schadendorf, K. Flaherty, 2012 .

METRIC phase III study: Efficacy of trametinib (T), a potent and selective MEK inhibitor (MEKi), in progression-free survival (PFS) and overall survival (OS), compared with chemotherapy (C) in patients (pts) with BRAFV600E/K mutant advanced or metastatic melanoma (MM).

J. Utikal, D. Schadendorf, K. Flaherty, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Patterns of care and follow-up care of patients with uveal melanoma in German-speaking countries: a multinational survey of the German Dermatologic Cooperative Oncology Group (DeCOG)

A. Enk, C. Berking, S. Haferkamp, 2020, Journal of Cancer Research and Clinical Oncology.

Adjuvant Therapy of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Patients With Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915)

D. Schadendorf, P. Ascierto, P. Queirolo, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

S. D'Angelo, S. Nolte, M. Schlichting, 2020, Future oncology.

Side effect management during immune checkpoint blockade using CTLA‐4 and PD‐1 antibodies for metastatic melanoma – an update

K. Kähler, S. Ugurel, L. Heinzerling, 2020, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

Quantitative Dynamic 18F-FDG PET/CT in Survival Prediction of Metastatic Melanoma under PD-1 Inhibitors

A. Dimitrakopoulou-Strauss, U. Haberkorn, A. Kopp-Schneider, 2021, Cancers.

Anti‐PD‐1 antibodies in metastatic uveal melanoma: a treatment option?

A. Enk, R. Gutzmer, J. Hassel, 2017, Cancer medicine.

Use of LDH and autoimmune side effects to predict response to ipilimumab treatment.

A. Enk, A. Dimitrakopoulou-Strauss, A. Kopp-Schneider, 2016, Immunotherapy.

18F-FDG PET/CT Reveals Disease Remission in a Patient With Ipilimumab-Refractory Advanced Melanoma Treated With Pembrolizumab.

A. Dimitrakopoulou-Strauss, J. Hassel, C. Sachpekidis, 2016, Clinical nuclear medicine.

Escalating therapy of cutaneous side effects of EGFR inhibitors: experience of German reference centers

A. Hauschild, R. Gutzmer, A. Wollenberg, 2012, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

Hematological immune related adverse events after treatment with immune checkpoint inhibitors.

C. Berking, A. Gesierich, K. Kähler, 2021, European journal of cancer.

5-year results for pembrolizumab treatment of advanced melanoma.

J. Hassel, 2019, The Lancet. Oncology.

Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced Melanoma.

J. Wolchok, M. Atkins, J. Kirkwood, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Metastatic melanoma response to combination therapy with ipilimumab and vemurafenib.

A. Dimitrakopoulou-Strauss, J. Hassel, C. Sachpekidis, 2017, Hellenic journal of nuclear medicine.

Long-Lasting Responses under Treatment with Ipilimumab: An Argument against Maintenance Therapy?

A. Enk, J. Hassel, J. Dick, 2014, Dermatology.

Combined immunotherapy with nivolumab and ipilimumab with and without local therapy in patients with melanoma brain metastasis: a DeCOG* study in 380 patients

C. Berking, S. Haferkamp, A. Gesierich, 2020, Journal for ImmunoTherapy of Cancer.

Sorafenib and pegylated interferon-α2b in advanced metastatic melanoma: a multicenter phase II DeCOG trial.

M. Weichenthal, C. Berking, A. Hauschild, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

Treatment Motivations and Expectations in Patients with Actinic Keratosis: A German-Wide Multicenter, Cross-Sectional Trial

J. Utikal, C. Berking, K. Kähler, 2020, Journal of clinical medicine.

Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma.

R. Sullivan, R. Dummer, J. Kirkwood, 2021, The New England journal of medicine.

Overall survival benefit from tebentafusp in patients with best response of progressive disease.

R. Sullivan, R. Dummer, J. Kirkwood, 2021 .

Reinduction of PD1-inhibitor therapy: first experience in eight patients with metastatic melanoma

R. Gutzmer, J. Hassel, M. Sachse, 2017, Melanoma research.

Impact of radiation, systemic therapy and treatment sequencing on survival of patients with melanoma brain metastases.

J. Utikal, C. Berking, S. Löck, 2019, European journal of cancer.

Response durability after cessation of immune checkpoint inhibitors in patients with metastatic Merkel cell carcinoma: a retrospective multicenter DeCOG study

J. Becker, S. Ugurel, C. Loquai, 2021, Cancer Immunology, Immunotherapy.

Long-term neurocognitive function after whole-brain radiotherapy in patients with melanoma brain metastases in the era of immunotherapy

A. Enk, M. Salzmann, J. Hassel, 2022, Strahlentherapie und Onkologie.

Cytokine release syndrome-like serum responses after COVID-19 vaccination are frequent and clinically inapparent under cancer immunotherapy

A. Schneeweiss, N. Halama, D. Jäger, 2022, Nature Cancer.

Male fertility during and after immune checkpoint inhibitor therapy: A cross-sectional pilot study.

A. Enk, D. Schadendorf, M. Salzmann, 2021, European journal of cancer.

STAT5 expression correlates with recurrence and survival in melanoma patients treated with interferon-&agr;

K. Buder-Bakhaya, D. Schadendorf, A. Sucker, 2018, Melanoma research.

Characteristics of immune checkpoint inhibitor-induced encephalitis and comparison with HSV-1 and anti-LGI1 encephalitis: A retrospective multicentre cohort study.

A. Gesierich, K. Kähler, S. Ugurel, 2022, European journal of cancer.

How we identify and treat neuromuscular toxicity induced by immune checkpoint inhibitors

J. Hassel, K. Jordan, B. Jordan, 2021, ESMO open.

Four cases of erysipelas‐like inflammation in patients with metastatic melanoma treated with checkpoint inhibitors

L. Heinzerling, J. Hassel, C. Pföhler, 2020, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

Severe Ocular Myositis After Ipilimumab Treatment for Melanoma: A Report of 2 Cases.

A. Enk, A. Dimitrakopoulou-Strauss, U. Neuberger, 2017, Journal of immunotherapy.

Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders.

R. Sullivan, J. Sosman, Douglas B. Johnson, 2016, JAMA oncology.

Safety of the PD-1 antibody pembrolizumab in patients with high-grade adverse events under ipilimumab treatment.

A. Enk, A. Dimitrakopoulou-Strauss, J. Hassel, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Treatment of Indolent Cutaneous B-Cell Lymphoma with Intralesional or Intravenous Rituximab

Adriana Rendon, J. Hassel, C. Menzer, 2022, Cancers.

Long-Term Management of Advanced Basal Cell Carcinoma: Current Challenges and Future Perspectives

C. Berking, M. Alter, M. Heppt, 2022, Cancers.

Nivolumab in previously untreated melanoma without BRAF mutation.

D. Schadendorf, K. Savage, C. Horak, 2015, The New England journal of medicine.

Five-Year Outcomes With Nivolumab in Patients With Wild-Type BRAF Advanced Melanoma

D. Schadendorf, K. Savage, P. Ascierto, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

LBA3_PRA PHASE 3 RANDOMIZED, OPEN-LABEL STUDY OF NIVOLUMAB (ANTI-PD-1; BMS-936558; ONO-4538) VERSUS INVESTIGATOR'S CHOICE CHEMOTHERAPY (ICC) IN PATIENTS WITH ADVANCED MELANOMA AFTER PRIOR ANTI-CTLA-4 THERAPY

G. Linette, F. Hodi, S. D'Angelo, 2014 .

789 Lifileucel TIL cell monotherapy in patients with advanced melanoma after progression on immune checkpoint inhibitors (ICI) and targeted therapy: pooled analysis of consecutive cohorts (C-144–01 study)

J. Kirkwood, P. Hari, H. Kluger, 2022, Regular and Young Investigator Award Abstracts.

Clinical and molecular response to tebentafusp in previously treated patients with metastatic uveal melanoma: a phase 2 trial

Douglas B. Johnson, E. Espinosa, A. Shoushtari, 2022, Nature Medicine.

1213OCharacterization of complete responses (CRs) in patients with advanced melanoma (MEL) who received the combination of nivolumab (NIVO) and ipilimumab (IPI), NIVO or IPI alone

D. Schadendorf, P. Ascierto, J. Wolchok, 2017 .

The n e w e n g l a n d j o u r n a l of m e d i c i n e Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

D. Schadendorf, G. Linette, J. Wolchok, 2022 .

MEK inhibitors for pre-treated, NRAS-mutated metastatic melanoma: A multi-centre, retrospective study.

A. Enk, D. Schadendorf, S. Ugurel, 2022, European journal of cancer.

Raster‐scanned intensity‐controlled carbon ion therapy for mucosal melanoma of the paranasal sinus

J. Debus, N. Chaudhri, J. Hassel, 2016, Head & neck.

Adenoviruses Using the Cancer Marker EphA2 as a Receptor In Vitro and In Vivo by Genetic Ligand Insertion into Different Capsid Scaffolds

A. Enk, D. Nettelbeck, F. Neipel, 2014, PloS one.

Lecithin retinol acyltransferase as a potential prognostic marker for malignant melanoma

D. Schadendorf, A. Bazhin, S. Eichmüller, 2013, Experimental dermatology.

Livid macules on the forehead after photodynamic therapy

A. Enk, T. Mentzel, J. Hassel, 2015, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

J. Hassel, S. B. Strobel, D. Machiraju, 2021, Cancer Immunology, Immunotherapy.

First-line (1L) avelumab treatment in patients (pts) with metastatic Merkel cell carcinoma (mMCC): Preliminary data from an ongoing study.

S. D'Angelo, C. Lebbé, P. Terheyden, 2017 .

Adjuvant ipilimumab compared with observation in completely resected Merkel cell carcinoma (ADMEC): A randomized, multicenter DeCOG/ADO study.

C. Berking, D. Schadendorf, K. Kähler, 2018 .

Safe Administration of An Anti-PD-1 Antibody to Kidney-transplant Patients: 2 Clinical Cases and Review of the Literature.

A. Enk, J. Winkler, R. Gutzmer, 2017, Journal of immunotherapy.

Malignant Melanoma S3‐Guideline “Diagnosis, Therapy and Follow‐up of Melanoma”

M. Weichenthal, A. Hauschild, D. Schadendorf, 2013, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

Differential Clinical Significance of Individual NKG2D Ligands in Melanoma: Soluble ULBP2 as an Indicator of Poor Prognosis Superior to S100B

D. Schadendorf, J. Becker, S. Ugurel, 2009, Clinical Cancer Research.

Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy

Özlem Türeci, Ugur Sahin, Heinrich Haas, 2016, Nature.

Phenol Chemical Matricectomy Is Less Painful, with Shorter Recovery Times but Higher Recurrence Rates, Than Surgical Matricectomy: A Patient's View

J. Hassel, C. Löser, A. Hassel, 2010, Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.].

Adenovirus-mediated intralesional interferon-gamma gene transfer induces tumor regressions in cutaneous lymphomas.

R. Dummer, G. Burg, S. Eichmüller, 2004, Blood.

Managing scleromyxedema with intravenous immunoglobulin: acute worsening of scleromyxedema with biclonal gammopathy.

S. Goerdt, J. Hassel, C. Loeser, 2010, Acta dermatovenerologica Alpina, Pannonica, et Adriatica.

Immunotherapy with ipilimumab plus nivolumab in a stage IV melanoma patient during pregnancy.

A. Enk, D. Jäger, E. Richtig, 2018, European journal of cancer.

Microscopically controlled surgery (MCS)

J. Hafner, J. Hassel, U. Hohenleutner, 2010, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

Programmed cell death protein 1 inhibitors in advanced cutaneous squamous cell carcinoma: real-world data of a retrospective, multicenter study.

A. Enk, S. Ugurel, M. Salzmann, 2020, European journal of cancer.

Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis

R. Sullivan, W. Rathmell, J. Sosman, 2018, JAMA oncology.

S1 guideline: microscopically controlled surgery (MCS)

J. Hafner, J. Hassel, U. Hohenleutner, 2015, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

Limitations of Ber‐EP4 for distinction of Bowen disease from basal cell carcinoma

F. Toberer, A. Enk, J. Hassel, 2016, Journal of cutaneous pathology.

Genetic characterization of advanced conjunctival melanoma and response to systemic treatment.

D. Schadendorf, P. Jansen, K. Kähler, 2022, European journal of cancer.

S3‐Guideline “Diagnosis, therapy and follow‐up of melanoma” – short version

M. Weichenthal, A. Hauschild, D. Schadendorf, 2013, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

Radiopharmaceutical Therapy of Patients with Metastasized Melanoma with the Melanin-Binding Benzamide 131I-BA52

A. Enk, U. Haberkorn, F. Giesel, 2014, The Journal of Nuclear Medicine.

Abstract 1673: Uveal melanoma study patients with low CD163:CD3 ratio in tumor biopsy and low serum IL-6 showed enhanced tumor shrinkage (TS) and overall survival (OS) on tebentafusp

L. Collins, J. Sacco, J. Hassel, 2021, Immunology.

An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma

J. Utikal, Ö. Türeci, U. Şahin, 2020, Nature.

Tadalafil has biologic activity in human melanoma. Results of a pilot trial with Tadalafil in patients with metastatic Melanoma (TaMe)

A. Enk, J. Utikal, N. Halama, 2017, Oncoimmunology.

Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis.

K. Savage, J. Wolchok, J. Larkin, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Potential Reasons for Unresponsiveness to Anti-PD1 Immunotherapy in Young Patients with Advanced Melanoma

J. Hassel, D. Machiraju, S. Schäfer, 2021, Life.

Biomarkers for Clinical Benefit of Immune Checkpoint Inhibitor Treatment—A Review From the Melanoma Perspective and Beyond

K. Buder-Bakhaya, J. Hassel, 2018, Front. Immunol..

Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab

D. Schadendorf, B. Schilling, P. Ascierto, 2016, Clinical Cancer Research.

Improved survival with MEK Inhibition in BRAF-mutated melanoma for the METRIC Study Group

Dirk Schadendorf, Peter Mohr, Reinhard Dummer, 2012 .

Human innate immune cell crosstalk induces melanoma cell senescence

K. Schäkel, J. Sleeman, A. Cerwenka, 2020, Oncoimmunology.

The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma.

A. McKenna, K. Cibulskis, S. Gabriel, 2014, Cancer discovery.

Immunotherapy of Melanoma

A. Enk, J. Hassel, C. Bender, 2016, Oncology Research and Treatment.

Anti‐programmed cell death‐1 therapy in nonmelanoma skin cancer

R. Schneiderbauer, A. Enk, S. Fröhling, 2017, The British journal of dermatology.

Identification of a tumor-reactive T-cell repertoire in the immune infiltrate of patients with resectable pancreatic ductal adenocarcinoma

N. Halama, A. Trumpp, M. Büchler, 2016, Oncoimmunology.

Evaluation of radio-immunotherapy sequence on immunological responses and clinical outcomes in patients with melanoma brain metastases (ELEKTRA)

R. Spang, A. Enk, M. Salzmann, 2022, Oncoimmunology.

Genetic profiling of melanoma in routine diagnostics: assay performance and molecular characteristics in a consecutive series of 274 cases.

A. Enk, S. Fröhling, P. Schirmacher, 2018, Pathology.

Melanoma and immunotherapy bridge 2015

Andrew J. Park, A. Hauschild, J. Malvehy, 2016, Journal of Translational Medicine.

Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab

C. Berking, D. Schadendorf, B. Schilling, 2016, Clinical Cancer Research.

Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab

R. Sullivan, J. Sosman, J. McQuade, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Targeted Therapy in Advanced Melanoma With Rare BRAF Mutations.

A. Enk, B. Schilling, Douglas B. Johnson, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

MGMT gene promoter methylation correlates with tolerance of temozolomide treatment in melanoma but not with clinical outcome

D. Schadendorf, H. Kurzen, R. Dummer, 2010, British Journal of Cancer.

Survival Outcomes in Patients With Previously Untreated BRAF Wild-Type Advanced Melanoma Treated With Nivolumab Therapy: Three-Year Follow-up of a Randomized Phase 3 Trial

D. Schadendorf, K. Savage, P. Ascierto, 2019, JAMA oncology.

Clinical and molecular characteristics associated with response to therapeutic PD-1/PD-L1 inhibition in advanced Merkel cell carcinoma

J. Utikal, S. Haferkamp, D. Schadendorf, 2022, Journal for ImmunoTherapy of Cancer.

Arsenic trioxide down-regulates antiapoptotic genes and induces cell death in mycosis fungoides tumors in a mouse model.

A. Navarini, J. Hassel, U. Döbbeling, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

Combined immune checkpoint blockade (anti-PD-1/anti-CTLA-4): Evaluation and management of adverse drug reactions.

N. Reinmuth, L. Heinzerling, J. Trojan, 2017, Cancer treatment reviews.

The BRAF Inhibitor Vemurafenib Enhances UV-Induced Skin Carcinogenesis in Beta HPV38 E6 and E7 Transgenic Mice.

M. Pawlita, C. Flechtenmacher, M. Tommasino, 2017, The Journal of investigative dermatology.

A multicenter DeCOG study on predictors of vemurafenib therapy outcome in melanoma: pretreatment impacts survival.

J. Utikal, C. Berking, D. Schadendorf, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Chemotherapy after immune checkpoint inhibitor failure in metastatic melanoma: a retrospective multicentre analysis

K. Buder-Bakhaya, A. Hauschild, D. Schadendorf, 2022, European Journal of Cancer.

Immune checkpoint inhibitors in patients with pre-existing psoriasis: safety and efficacy

J. Sosman, M. Lacouture, Douglas B. Johnson, 2021, Journal for ImmunoTherapy of Cancer.

Lipase elevation and type 1 diabetes mellitus related to immune checkpoint inhibitor therapy - A multicentre study of 90 patients from the German Dermatooncology Group.

J. Utikal, C. Berking, K. Kähler, 2021, European journal of cancer.

Arthralgia Induced by BRAF Inhibitor Therapy in Melanoma Patients

A. Enk, K. Buder-Bakhaya, M. Salzmann, 2020, Cancers.

Melanoma brain metastases - Interdisciplinary management recommendations 2020.

D. Schadendorf, R. Gutzmer, D. Vordermark, 2020, Cancer treatment reviews.

Combined immune checkpoint blockade for metastatic uveal melanoma: a retrospective, multi-center study

J. Utikal, C. Berking, A. Gesierich, 2019, Journal of Immunotherapy for Cancer.

Postoperative Radiotherapy and the Role of Regional Lymph Node Irradiation in Localized Merkel Cell Carcinoma: A Single-Center Retrospective Analysis

J. Debus, J. Hörner-Rieber, J. Hassel, 2022, Cancers.

Serological Immunomarkers in Cutaneous T Cell Lymphoma

H. Joller-jemelka, R. Dummer, G. Burg, 2004, Dermatology.

Cytokine alterations during paraneoplastic neutrophilia and leukemoid reaction in patients with advanced melanoma

M. Salzmann, N. Halama, J. Hassel, 2022, Cancer Immunology, Immunotherapy.

787O Adjuvant immunotherapy with nivolumab (NIVO) versus observation in completely resected Merkel cell carcinoma (MCC): Disease-free survival (DFS) results from ADMEC-O, a randomized, open-label phase II trial

A. Hauschild, S. Haferkamp, D. Schadendorf, 2022, Annals of Oncology.

Rituximab as a therapeutic option for patients with advanced melanoma

A. Enk, J. Winkler, M. Schiller, 2018, Cancer Immunology, Immunotherapy.

Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial

J. Utikal, C. Berking, A. Hauschild, 2020, The Lancet.

First-line avelumab in a cohort of 116 patients with metastatic Merkel cell carcinoma (JAVELIN Merkel 200): primary and biomarker analyses of a phase II study

Parantu K. Shah, J. Grob, C. Lebbé, 2021, Journal for ImmunoTherapy of Cancer.

Reinduction of Hedgehog Inhibitors after Checkpoint Inhibition in Advanced Basal Cell Carcinoma: A Series of 12 Patients

R. Gutzmer, J. Hassel, M. Sachse, 2022, Cancers.

Differential in fl uence of vemurafenib and dabrafenib on patients ’ lymphocytes despite similar clinical ef fi cacy in melanoma

J. Utikal, C. Berking, D. Schadendorf, 2014 .

Phase II trial of ipilimumab in melanoma patients with preexisting humoural immune response to NY-ESO-1.

A. Enk, N. Halama, L. Umansky, 2018, European journal of cancer.

Monitoring targeted therapy using dual-energy CT: semi-automatic RECIST plus supplementary functional information by quantifying iodine uptake of melanoma metastases

H. Schlemmer, M. Sedlmair, M. Ganten, 2013, Cancer imaging : the official publication of the International Cancer Imaging Society.

Therapy response assessment in metastatic melanoma patients treated with a BRAF inhibitor: adapted Choi criteria can reflect early therapy response better than does RECIST.

H. Schlemmer, M. Ganten, J. Hassel, 2013, Academic radiology.

Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator's Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial.

D. Schadendorf, G. Linette, C. Horak, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

18F-FDG PET/CT longitudinal studies in patients with advanced metastatic melanoma for response evaluation of combination treatment with vemurafenib and ipilimumab

L. Hakim-Meibodi, A. Dimitrakopoulou-Strauss, A. Kopp-Schneider, 2019, Melanoma research.

Immunotherapy Bridge 2021 and Melanoma Bridge 2021: meeting abstracts

R. Sullivan, R. Dummer, J. Kirkwood, 2022, Journal of Translational Medicine.

First-line therapy-stratified survival in BRAF-mutant melanoma: a retrospective multicenter analysis

D. Schadendorf, B. Schilling, A. Gesierich, 2019, Cancer Immunology, Immunotherapy.

Upstream mitogen-activated protein kinase (MAPK) pathway inhibition: MEK inhibitor followed by a BRAF inhibitor in advanced melanoma patients.

Dirk Schadendorf, Axel Hauschild, Reinhard Dummer, 2014, European journal of cancer.

Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study

Michael E. Egger, J. Kirkwood, P. Hari, 2022, Journal for ImmunoTherapy of Cancer.

Prophylaxis and Management of Skin Toxicities

M. Salzmann, F. Marmé, J. Hassel, 2019, Breast Care.

Programmed cell death protein-1 (PD-1) inhibitor therapy in patients with advanced melanoma and preexisting autoimmunity or ipilimumab-triggered autoimmunity.

A. Gesierich, K. Kähler, S. Ugurel, 2017, European journal of cancer.

Subcutaneous endometriosis mimicking melanoma metastasis

F. Toberer, A. Enk, K. Buder-Bakhaya, 2019, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

Radiosensitization by BRAF inhibitors

A. Enk, L. Zimmer, J. Hassel, 2017, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

Tolerability of BRAF/MEK inhibitor combinations: adverse event evaluation and management

L. Heinzerling, R. Gutzmer, A. Vogel, 2019, ESMO Open.

Histogram analysis of iodine maps from dual energy computed tomography for monitoring targeted therapy of melanoma patients.

H. Schlemmer, M. Ganten, D. Simons, 2015, Future oncology.

Progression patterns under BRAF inhibitor treatment and treatment beyond progression in patients with metastatic melanoma

K. Buder-Bakhaya, S. Ugurel, R. Gutzmer, 2017, Cancer medicine.

Vemurafenib and ipilimumab: A promising combination? Results of a case series

A. Enk, D. Jäger, A. Dimitrakopoulou-Strauss, 2016, Oncoimmunology.

RAS mutations in benign epithelial tumors associated with BRAF inhibitor treatment of melanoma.

W. Weichert, C. Hafner, J. Hassel, 2015, The Journal of investigative dermatology.

[Melanoma: introduction and special demands on radiology].

M. Schiller, J. Hassel, 2015, Der Radiologe.

Soluble immune checkpoints and T-cell subsets in blood as biomarkers for resistance to immunotherapy in melanoma patients

A. Enk, N. Halama, J. Hassel, 2021, Oncoimmunology.

GNAQ and GNA11 mutant nonuveal melanoma: a subtype distinct from both cutaneous and uveal melanoma

J. Utikal, D. Schadendorf, B. Schilling, 2020, The British journal of dermatology.

Cytokine release syndrome-like serum responses after COVID-19 vaccination are frequent but clinically inapparent in cancer patients under immune checkpoint therapy

A. Schneeweiss, N. Halama, D. Jäger, 2021, medRxiv.

Effect of nivolumab on health-related quality of life in patients with treatment-naïve advanced melanoma: results from the phase III CheckMate 066 study

A. Abernethy, K. Savage, P. Ascierto, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Early Exanthema Upon Vemurafenib Plus Cobimetinib Is Associated With a Favorable Treatment Outcome in Metastatic Melanoma: A Retrospective Multicenter DeCOG Study

J. Utikal, D. Schadendorf, A. Gesierich, 2021, Frontiers in Oncology.

Development and validation of a web-based patient decision aid for immunotherapy for patients with metastatic melanoma: study protocol for a multicenter randomized trial

M. Salzmann, B. Wild, W. Eich, 2021, Trials.

S100 as Serum Tumor Marker in Advanced Uveal Melanoma

A. Enk, M. Salzmann, J. Hassel, 2023, Biomolecules.

Factors Influencing the Adjuvant Therapy Decision: Results of a Real-World Multicenter Data Analysis of 904 Melanoma Patients

C. Berking, D. Schadendorf, B. Schilling, 2021, Cancers.

Which melanoma patient carries a BRAF-mutation? A comparison of predictive models

L. Heinzerling, C. Garbe, M. Berneburg, 2016, Oncotarget.

Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders (AD) or major toxicity with ipilimumab (IPI).

R. Sullivan, J. Sosman, J. McQuade, 2016 .

Real-World Therapy with Pembrolizumab: Outcomes and Surrogate Endpoints for Predicting Survival in Advanced Melanoma Patients in Germany

M. Weichenthal, J. Utikal, C. Berking, 2022, Cancers.

Adjuvant nivolumab plus ipilimumab or nivolumab alone versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): final results of a randomised, double-blind, phase 2 trial

J. Utikal, C. Berking, A. Hauschild, 2022, The Lancet.

Five-year outcomes from a phase 3 METRIC study in patients with BRAF V600 E/K-mutant advanced or metastatic melanoma.

J. Utikal, D. Schadendorf, K. Flaherty, 2019, European journal of cancer.

Autoantibodies as Predictors for Clinical Outcome and Toxicity for Immunotherapy.

J. Luke, J. Hassel, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

Abstract CT004: Adjuvant therapy with nivolumab (NIVO) combined with ipilimumab (IPI) vs NIVO alone in patients (pts) with resected stage IIIB-D/IV melanoma (CheckMate 915)

D. Schadendorf, P. Ascierto, P. Queirolo, 2021, Clinical Trials.

Characterization of arthralgia induced by PD-1 antibody treatment in patients with metastasized cutaneous malignancies

A. Enk, K. Buder-Bakhaya, A. Dimitrakopoulou-Strauss, 2018, Cancer Immunology, Immunotherapy.

Assessment of early metabolic progression in melanoma patients under immunotherapy: an 18F-FDG PET/CT study

A. Dimitrakopoulou-Strauss, A. Kopp-Schneider, J. Hassel, 2021, EJNMMI Research.

Axillary accessory breast tissue – case report and review of literature

A. Enk, J. Hassel, M. Bidier, 2014, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

“UniCAR”-modified off-the-shelf NK-92 cells for targeting of GD2-expressing tumour cells

D. Jäger, B. Seliger, W. Wels, 2020, Scientific Reports.

Melanoma and immunotherapy bridge 2015

Andrew J. Park, David C. Smith, A. Hauschild, 2016, Journal of Translational Medicine.

Predictive value of early 18F-FDG PET/CT studies for treatment response evaluation to ipilimumab in metastatic melanoma: preliminary results of an ongoing study

A. Dimitrakopoulou-Strauss, U. Haberkorn, L. Larribère, 2014, European Journal of Nuclear Medicine and Molecular Imaging.

The utility of chemotherapy after immunotherapy failure in metastatic melanoma: A multicenter case series.

A. Gesierich, P. Ascierto, R. Dummer, 2018 .

Effectiveness and Tolerability of Ipilimumab: Experiences From 198 Patients Included in a Named-Patient Program in Various Daily-Practice Settings and Multiple Institutions

A. Hauschild, K. Kähler, C. Garbe, 2014, Journal of immunotherapy.

“UniCAR”-modified off-the-shelf NK-92 cells for targeting of GD2-expressing tumour cells

D. Jäger, B. Seliger, W. Wels, 2020, Scientific Reports.

An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma

J. Utikal, Ö. Türeci, U. Şahin, 2020, Nature.

Retrospective Side Effect Profiling of the Metastatic Melanoma Combination Therapy Ipilimumab-Nivolumab Using Adverse Event Data

Theodoros G. Soldatos, A. Dimitrakopoulou-Strauss, L. Larribère, 2018, Diagnostics.

Pleomorphic dermal sarcoma with cerebral metastasis

A. Enk, L. Trennheuser, J. Hassel, 2020, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

Spiny keratoderma of the palms and soles – once seen, never forgotten

M. Gaiser, J. Hassel, I. Hausser, 2017, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

Outcome of melanoma patients with elevated LDH treated with first-line targeted therapy or PD-1-based immune checkpoint inhibition.

C. Berking, D. Schadendorf, B. Schilling, 2021, European journal of cancer.

STAT5 Contributes to Interferon Resistance of Melanoma Cells

J. Becker, M. Schartl, P. Heinrich, 2005, Current Biology.

Co-primary endpoint of overall survival for tebentafusp (tebe)-induced rash in a phase 3 randomized trial comparing tebe versus investigator’s choice (IC) in first-line metastatic uveal melanoma.

R. Sullivan, R. Dummer, J. Kirkwood, 2021 .

64MO A phase (ph) II, multi-center study of the safety and efficacy of tebentafusp (tebe) (IMCgp100) in patients (pts) with metastatic uveal melanoma (mUM)

Takuro Sato, Douglas B. Johnson, E. Espinosa, 2020 .

Dataset of a retrospective multicenter cohort study on characteristics of immune checkpoint inhibitor-induced encephalitis and comparison with HSV-1 and anti-LGI1 encephalitis

A. Gesierich, K. Kähler, S. Ugurel, 2022, Data in brief.

1082MO 5-year characterization of complete responses in patients with advanced melanoma who received nivolumab plus ipilimumab (NIVO+IPI) or NIVO alone

D. Schadendorf, P. Ascierto, J. Wolchok, 2020 .

Complete Metabolic Response in FDG-PET-CT Scan before Discontinuation of Immune Checkpoint Inhibitors Correlates with Long Progression-Free Survival

A. Enk, A. Stenzinger, A. Dimitrakopoulou-Strauss, 2021, Cancers.

Longitudinal studies of the 18F-FDG kinetics after ipilimumab treatment in metastatic melanoma patients based on dynamic FDG PET/CT

Annette Kopp-Schneider, Uwe Haberkorn, Antonia Dimitrakopoulou-Strauss, 2018, Cancer Immunology, Immunotherapy.

Absolute number of new lesions on 18F-FDG PET/CT is more predictive of clinical response than SUV changes in metastatic melanoma patients receiving ipilimumab

Annette Kopp-Schneider, Uwe Haberkorn, Antonia Dimitrakopoulou-Strauss, 2018, European Journal of Nuclear Medicine and Molecular Imaging.

Promising Results from a Pilot Study on Compression Treatment of Ear Keloids

J. Hassel, C. Löser, A. Hassel, 2011, Journal of cutaneous medicine and surgery.

Compression Treatment of Ear Keloids by a Modified Oyster Splint Technique

J. Hassel, A. Hassel, A. Kreuter, 2013 .

Treatment of Ear Keloids by Compression, Using a Modified Oyster‐Splint Technique

P. Rammelsberg, J. Hassel, A. Hassel, 2007, Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.].

Treatment of ear keloids by the oyster-splint technique

P. Rammelsberg, J. Hassel, C. Löser, 2007 .

Skin Care During and After Radiotherapy and Anticancer Treatment

M. Salzmann, J. Hassel, U. Höller, 2019, Radiation Oncology.

Targeting the cMET pathway to enhance immunotherapeutic approaches for mUM patients

J. Hassel, D. Machiraju, 2023, Frontiers in Oncology.

Application of the long axial field-of-view PET/CT with low-dose [18F]FDG in melanoma

A. Dimitrakopoulou-Strauss, A. Kopp-Schneider, J. Hassel, 2022, European Journal of Nuclear Medicine and Molecular Imaging.

Clinical outcome of concomitant vs interrupted BRAF inhibitor therapy during radiotherapy in melanoma patients

J. Utikal, C. Berking, D. Schadendorf, 2018, British Journal of Cancer.

Susceptibility‐weighted imaging in malignant melanoma brain metastasis

S. Heiland, H. Schlemmer, S. Delorme, 2019, Journal of magnetic resonance imaging : JMRI.

Deep abscopal response to radiotherapy and anti-PD-1 in an oligometastatic melanoma patient with unfavorable pretreatment immune signature

A. Abdollahi, D. von Bubnoff, A. Grosu, 2020, Cancer Immunology, Immunotherapy.

The prognostic value of [18F]FDG PET/CT based response monitoring in metastatic melanoma patients undergoing immunotherapy: comparison of different metabolic criteria

A. Dimitrakopoulou-Strauss, A. Kopp-Schneider, J. Hassel, 2023, European Journal of Nuclear Medicine and Molecular Imaging.

Positron Emission Tomography-Based Immunoimaging for Cancer Patient Stratification: Toward a More Holistic Approach.

A. Dimitrakopoulou-Strauss, J. Hassel, C. Sachpekidis, 2022, Cancer biotherapy & radiopharmaceuticals.

Molecular prediction of clinical response to anti‐PD‐1/anti‐PD‐L1 immune checkpoint inhibitors: New perspectives for precision medicine and mass spectrometry‐based investigations

R. Longuespée, W. Haefeli, I. Zörnig, 2022, International journal of cancer.

COOLHAIR: a prospective randomized trial to investigate the efficacy and tolerability of scalp cooling in patients undergoing (neo)adjuvant chemotherapy for early breast cancer

A. Schneeweiss, C. Sohn, F. Marmé, 2018, Breast Cancer Research and Treatment.

Varicella-Like Cutaneous Toxoplasmosis in a Patient with Aplastic Anemia

P. Schnitzler, J. Hassel, A. Dalpke, 2013, Journal of Clinical Microbiology.

A shared tumor-antigen RNA-lipoplex vaccine with/without anti-PD1 in patients with checkpoint-inhibition experienced melanoma.

J. Utikal, Ö. Türeci, U. Şahin, 2020 .

Liquid Biopsy: Value for Melanoma Therapy?

K. Buder-Bakhaya, J. Hassel, D. Machiraju, 2017, Oncology Research and Treatment.

PD‐1 blockade: a therapeutic option for treatment of metastatic Merkel cell carcinoma

A. Enk, J. Winkler, C. Kratochwil, 2017, The British journal of dermatology.

Macroangiopathy is a positive predictive factor for response to immunotherapy

H. Schlemmer, A. Radbruch, O. Sedlaczek, 2019, RöFo - Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren.

Surveillance of patients with conjunctival melanoma in German-speaking countries: A multinational survey of the German dermatologic cooperative oncology group.

A. Enk, C. Berking, S. Haferkamp, 2020, European journal of cancer.

Nivolumab improved survival vs dacarbazine in patients with untreated advanced melanoma

D. Schadendorf, K. Savage, C. Horak, 2015, Journal of Translational Medicine.

Nivolumab improved survival vs dacarbazine in patients with untreated advanced melanoma

D. Schadendorf, K. Savage, C. Horak, 2015, Journal of Translational Medicine.

Rapid disease progression on immune checkpoint inhibitors in young patients with stage IV melanoma

J. Hassel, P. Beckhove, D. Machiraju, 2023, Frontiers in Medicine.

Editorial on the use of immunotherapy in renal-cell carcinoma—promising results in combination therapy with ipilimumab and nivolumab

J. Hassel, C. Menzer, C. Gruellich, 2017 .

Autoantibodies as predictors for survival and immune-related adverse events in checkpoint inhibition therapy of metastasized melanoma.

L. Hakim-Meibodi, R. Dummer, P. Budde, 2020 .

Persistent symptoms and risk factors predicting prolonged time to symptom-free after SARS‑CoV‑2 infection: an analysis of the baseline examination of the German COVIDOM/NAPKON-POP cohort

Sonja Kunze, S. Ugurel, R. Strobl, 2023, Infection.

Ipilimumab plus nivolumab for advanced melanoma.

J. Hassel, 2016, The Lancet. Oncology.

Immune Checkpoint Blockade for Metastatic Uveal Melanoma: Re-Induction following Resistance or Toxicity

M. Weichenthal, J. Utikal, C. Berking, 2022, Cancers.

Immune Checkpoint Blockade for Metastatic Uveal Melanoma: Patterns of Response and Survival According to the Presence of Hepatic and Extrahepatic Metastasis

M. Weichenthal, J. Utikal, C. Berking, 2021, Cancers.

Abstract CT002: Phase 3 randomized trial comparing tebentafusp with investigator's choice in first line metastatic uveal melanoma

R. Sullivan, R. Dummer, J. Kirkwood, 2021, Clinical Trials.

Chemotherapeutics, chemoresistance and the management of melanoma.

J. Hassel, K. Rass, 2009, Giornale italiano di dermatologia e venereologia : organo ufficiale, Societa italiana di dermatologia e sifilografia.

PD-L1 expression as a biomarker for nivolumab (NIVO) plus ipilimumab (IPI) and NIVO alone in advanced melanoma (MEL): A pooled analysis

D. Schadendorf, C. Horak, P. Ascierto, 2016 .

A first-in-human phase I/II clinical trial assessing novel mRNA-lipoplex nanoparticles encoding shared tumor antigens for immunotherapy of malignant melanoma.

J. Utikal, M. Gaiser, Ö. Türeci, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

49PA first-in-human phase I/II clinical trial assessing novel mRNA-lipoplex nanoparticles encoding shared tumor antigens for potent melanoma immunotherapy

J. Utikal, D. Jäger, Ö. Türeci, 2017 .

Abstract CT032: A first-in-human phase I/II clinical trial assessing novel mRNA-lipoplex nanoparticles for potent cancer immunotherapy in patients with malignant melanoma

J. Utikal, U. Şahin, M. Diken, 2016 .

Brain metastasis and survival outcomes after first-line therapy in metastatic melanoma: a multicenter DeCOG study on 1704 patients from the prospective skin cancer registry ADOREG

M. Weichenthal, J. Utikal, S. Haferkamp, 2023, Journal for ImmunoTherapy of Cancer.

Distinct immune-effector and metabolic profile of CD8+ T cells in patients with autoimmune polyarthritis induced by therapy with immune checkpoint inhibitors

Hanns-Martin Lorenz, J. Hassel, K. Klika, 2022, Annals of the Rheumatic Diseases.

1126P Prediction of clinical outcome by soluble immune checkpoints and T cell subsets in patients treated with immune checkpoint blockers for metastasized melanoma

J. Hassel, D. Machiraju, J. Roth, 2020 .

Immune checkpoint inhibition and targeted therapy for melanoma: A patient‐oriented cross‐sectional comparative multicentre study

S. Haferkamp, M. Gaiser, R. Gutzmer, 2022, Journal of the European Academy of Dermatology and Venereology : JEADV.

Adjuvant immunotherapy with nivolumab (NIVO) alone or in combination with ipilimumab (IPI) versus placebo in stage IV melanoma patients with no evidence of disease (NED): A randomized, double-blind phase II trial (IMMUNED)

A. Hauschild, D. Schadendorf, C. Garbe, 2019, Annals of Oncology.

Vemurafenib‐induced granuloma annulare

A. Enk, S. Ugurel, J. Hassel, 2016, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

Erythema nodosum‐like lesions during BRAF inhibitor therapy: Report on 16 new cases and review of the literature

C. Berking, K. Kähler, S. Ugurel, 2015, Journal of the European Academy of Dermatology and Venereology : JEADV.

Necrolytic migratory erythema in a patient with neuroendocrine carcinoma.

A. Enk, D. Jäger, M. Gronau, 2013, Internal medicine.

Tolerability of BRAF and MEK Inhibitors for Metastasized Melanoma after Intra-Class Switch: A Multicenter, Retrospective Study

A. Enk, M. Salzmann, L. Heinzerling, 2023, Cancers.

Chemovirotherapy of malignant melanoma with a targeted and armed oncolytic measles virus.

A. Enk, C. von Kalle, D. Nettelbeck, 2013, The Journal of investigative dermatology.

A phase II, multicenter study of encorafenib/binimetinib followed by a rational triple-combination after progression in patients with advanced BRAF V600-mutated melanoma (LOGIC2).

C. Berking, A. Gesierich, P. Ascierto, 2020 .

3310 LOGIC2: Phase 2, multi-center, open-label study of sequential encorafenib/binimetinib combination followed by a rational combination with targeted agents after progression, to overcome resistance in adult patients with locally-advanced or metastatic BRAF V600 melanoma

C. Berking, A. Gesierich, S. Jaeger, 2015 .

Abstract CT156: A first-in-human phase I/II clinical trial assessing novel mRNA-lipoplex nanoparticles encoding shared tumor antigens for immunotherapy of malignant melanoma

J. Utikal, D. Jäger, Ö. Türeci, 2018, Clinical Trials.

Abstract B041: A novel nanoparticular formulated tetravalent RNA cancer vaccine for treatment of patients with malignant melanoma

J. Utikal, U. Şahin, M. Diken, 2016 .

Checkpoint blocker induced autoimmunity as an indicator for tumour efficacy in melanoma

J. Hassel, 2021, British Journal of Cancer.

Tebentafusp in combination with durvalumab and/or tremelimumab in patients with metastatic cutaneous melanoma: a phase 1 study

P. Ascierto, J. Kirkwood, A. Shoushtari, 2023, Journal for ImmunoTherapy of Cancer.

Fractal and Multifractal Analysis of PET-CT Images for Therapy Assessment of Metastatic Melanoma Patients under PD-1 Inhibitors: A Feasibility Study

A. Dimitrakopoulou-Strauss, G. Matsopoulos, A. Provata, 2021, Cancers.

Fractal and multifractal analysis of PET/CT images of metastatic melanoma before and after treatment with ipilimumab

Leyun Pan, Antonia Dimitrakopoulou-Strauss, Theoharis Theoharis, 2015, EJNMMI Research.

Multiple alopecic patches in the hairy scalp area of a 28‐year‐old female patient

J. Hassel, C. Pixberg, A. Keller, 2021, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

IgE blockade in the management of eosinophil-associated recalcitrant pruritus due to medical tumor therapy.

R. Gutzmer, J. Hassel, V. Sibaud, 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

Adenovirus-mediated intralesional interferon-gamma gene transfer induces tumor regressions in cutaneous lymphomas.

R. Dummer, G. Burg, S. Eichmüller, 2004, Blood.

Fertilität, Kontrazeption und Teratogenität bei Immuncheckpointblockade

C. Berking, J. Hassel, 2023, Die Dermatologie.

Solitary, well-circumscribed, depressed palmar lesion.

F. Toberer, A. Enk, M. Hantschke, 2015, The American Journal of dermatopathology.

1222PDRegional differences in overall survival (OS) in patients with advanced melanoma (MEL) who received nivolumab (NIVO) combined with ipilimumab (IPI) or NIVO alone in a phase 3 trial (CheckMate 067)

D. Schadendorf, P. Ascierto, J. Wolchok, 2017 .

Macroangiopathy is a positive predictive factor for response to immunotherapy

H. Schlemmer, A. Radbruch, O. Sedlaczek, 2019, Scientific Reports.

[Multiple, flesh-coloured, firm, grouped papulonoduleson the right forehead].

F. Toberer, A. Enk, J. Hassel, 2011, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

Anti-PD1 plus BRAF/MEK inhibitors (triplet therapy) after failure of standard therapy in patients (pts) with advanced melanoma.

C. Berking, D. Schadendorf, S. Ugurel, 2023, Journal of Clinical Oncology.

Differential influence of vemurafenib and dabrafenib on patients' lymphocytes despite similar clinical efficacy in melanoma.

J. Utikal, C. Berking, D. Schadendorf, 2014 .

Cytokine alterations during paraneoplastic neutrophilia and leukemoid reaction in patients with advanced melanoma

M. Salzmann, N. Halama, J. Hassel, 2022, Cancer Immunology, Immunotherapy.

First-line therapy-stratified survival in BRAF-mutant melanoma: a retrospective multicenter analysis

D. Schadendorf, B. Schilling, A. Gesierich, 2019, Cancer Immunology, Immunotherapy.

Immunotherapy of Melanoma

A. Enk, A. Rotte, Madhuri Bhandaru, 2016, Oncology Research and Treatment.

COOLHAIR: A prospective randomized trial to investigate the efficacy and tolerability of scalp cooling in patients undergoing neoadjuvant chemotherapy for early breast cancer.

A. Schneeweiss, C. Sohn, J. Heil, 2017 .

Cutis verticis gyrata-like skin toxicity during treatment of melanoma patients with the BRAF inhibitor vemurafenib after whole-brain radiotherapy is a consequence of the development of multiple follicular cysts and milia

A. Enk, F. Sterzing, J. Hassel, 2014, Strahlentherapie und Onkologie.

In vivo visualization of mesoscopic anatomy of healthy and pathological lymph nodes using 7T MRI: A feasibility study

M. Ladd, B. Stieltjes, H. Schlemmer, 2015, Journal of magnetic resonance imaging : JMRI.

Vemurafenib‐induced granuloma annulare

A. Enk, S. Ugurel, J. Hassel, 2016, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

Characterization of arthralgia induced by PD-1 antibody treatment in patients with metastasized cutaneous malignancies

A. Enk, K. Buder-Bakhaya, A. Dimitrakopoulou-Strauss, 2018, Cancer Immunology, Immunotherapy.